VVT Med Inc.VVTM.V
Health Care · Health Care Equipment & Services · TSX-V · Canada · vvtmed.com
VVT Med Inc. develops, manufactures and distributes minimally invasive, non-thermal, non-tumescent solutions for the treatment of vein disease, starting with varicose veins. Its FDA-cleared and CE-marked catheter-based technologies, ScleroSafe and V-Block, enable office-based procedures without anesthesia. The patent portfolio spans 55 patents from 14 families across 20 countries.
Key ratios
FCF / Sales
-3423.9%TTM
2025
-3555.0%2024
-185.2%2023
-3421.0%
Net margin
-211.4%TTM
2024
-211.4%
ROA
-170.0%2025
2024
-73.1%
Revenue growth
-83.2%TTM
2025
-81.9%2024
1100.0%
Recent news
VVT Med Closes Second Tranche of Private Placement of Units; Over $1.8M in Total Proceeds Raised
VVT Med Advances Portugal Market Entry as Dermworks Begins ScleroSafe® Market Evaluation and Announces Corporate Updates
VVT Med Announces Debt Settlement and Equity Incentive Grants to Strengthen Capital Structure
Track VVTM.V in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer